ADAlzheimer’s diseaseExplore the evidence ↗Global Health Challenges / Neurodegenerative Diseases
NeurodegenerationNeurodegenerative
Diseases
A connected perspective on nine neurodegenerative disease groups — from population evidence and diagnosis to therapeutic innovation, clinical research and long-term care.
Neurodegeneration research snapshotResearch datasets · 2026
9Disease groups
169Distinct products
241Mapped trials
52Trial countries listed
A connected research perspectiveSee the field.
Discover the connections.
9 disease groupsDiscover the connections.
Product pipeline196 indicationsProduct–indication records
Patient journey95 recordsCare-pathway evidence
Coverage of the supplied datasets; not a census of the entire field.
9 disease groupsone connected research view
169 productsacross 196 indication records
241 mapped trialswith a listed trial country
5 visualisationsexplore evidence and research
The full research scope
One field.
Nine paths to explore.
Go beyond a single diagnosis. Enter a disease profile to explore its evidence, follow therapeutic development and see where clinical research is happening — with one selection connecting all five views.
Select a disease to connect the five viewsExplore the evidence ↓
ADAlzheimer’s diseaseExplore the evidence ↗
PDParkinson’s diseaseExplore the evidence ↗
ALSAmyotrophic lateral sclerosisExplore the evidence ↗
HDHuntington’s diseaseExplore the evidence ↗
FTDFrontotemporal dementiaExplore the evidence ↗
DLBDementia with Lewy bodiesExplore the evidence ↗
MSAMultiple system atrophyExplore the evidence ↗
PSPProgressive supranuclear palsyExplore the evidence ↗
AtaxiasNeurodegenerative ataxiasExplore the evidence ↗Counts reflect the supplied research. “With Phase 3 evidence” counts distinct products with a verified Phase 3 record. Products and trials can appear in multiple disease groups. Images are conceptual illustrations.
A connected perspective
Understand the disease.
Connect the bigger picture.
Connect the work of researchers, innovators, care providers and partners. A broader view brings disease-specific needs into focus while making research coverage, care transitions and evidence gaps easier to explore.
Understanding the evidence. Keeping people in focus.
Understand the burdenExplore incidence and other population measures with their geography, age group, method and source context.
Follow the care pathwayConnect diagnosis, treatment and ongoing support with evidence at each stage and transition.
See the research landscapeExplore products, clinical phases, recorded regulatory events and trial participation across countries.
Population evidence
The geography of neurodegeneration
Explore incidence by disease and country, then switch to prevalence or deaths and DALYs. Compare eligible national records while keeping local studies and contextual evidence visible.
Estimates differ by year, age group and method. The map uses eligible national incidence records; other evidence remains available separately in the visualisation.
The care pathway
The patient journey
Explore the pathway from recognition and diagnosis to treatment and ongoing care. Select a disease and a pathway step to inspect the supporting evidence and gaps.
Records come from different studies and countries. They describe stages and transitions and should not be added together or read as a single patient cohort.
Therapeutic landscape
From development to regulatory decisions
Explore products by disease, modality, developer and recorded status. Clinical phase and regional regulatory events appear separately, with evidence available for individual product indications.
One row represents one product indication. Region codes identify recorded regulatory events, rather than a fully verified current marketing status in every jurisdiction.
Clinical research footprint
Where clinical trials take place
Explore the geography of the supplied trial dataset. Filter by disease, clinical phase and recorded status, and distinguish listed countries from confirmed participation or recruiting sites.
A country listed in a registry is not necessarily recruiting. Country participation and recruitment are separate views; unavailable status is kept distinct from confirmed activity.
Research and population need
Clinical trials vs. disease burden
Compare national incidence evidence with the distribution of trials. Switch between listed trials, confirmed participation and trials with a recruiting site to explore the available country matches.
Country comparisons depend on eligible incidence data and the selected trial definition. A missing match means evidence is unavailable in this dataset; it does not establish an absence of disease or research.
Look closer
Behind every number,
a new question.
Where is research concentrated? Which products have progressed furthest? Where does the care pathway break down? Follow the evidence and explore the field from a different angle.
The human pathway95 care-pathway evidence recordsResearch matters.
Research matters.
So does the journey.
Explore the evidence behind diagnosis, treatment and ongoing care — and the transitions that connect them.
Explore the patient journey ↗Clinical research↗
Where is the
research happening?
241 mapped trials.
52 listed countries.
Therapeutic development↗
From possibility
to clinical progress.
169 products.
Follow the evidence by phase.
Alzheimer’s20
Parkinson’s13
ALS4
Products with Phase 3 evidence · selected groupsBuild the next connection.
Partner with GHC ↗Bring your research, expertise or organisation into the conversation.
Read more
Research worth
a closer look.
Neurodegenerative Diseases Global Overview 2026. Start with the one-pager, explore the teaser or read the full analytical report.
Coming soon
Neurodegenerative Diseases Intelligence Platform
A planned hub connecting disease evidence, therapeutic development, clinical research and the patient journey.
- Disease evidence across nine disease groups
- Product intelligence with clinical phase and regulatory context
- Clinical research by geography and participation
- Care pathways with linked evidence and research gaps
The portal is in preparation. Explore the available research visualisations above.
Neurodegeneration IntelligenceOverviewProductsTrials
All diseasesResearch overviewConcept preview
Disease groups9
Products169
Mapped trials241
Countries listed52
Connected evidence
BurdenProductsTrialsCare
From population evidence to patient pathways
Research coverage
Product indications196
Population records164
Journey evidence95
Visualisations5
Coming soon Concept preview · supplied research datasets
Concept preview of the planned platform.
Advance neurodegeneration research with us
Partner on evidence, analytics and initiatives connecting research, innovation and care.
Research coverage: Supplied neurodegenerative disease visualisations and their linked sources. Counts describe these datasets and may differ between views. Listed trial countries do not imply confirmed recruitment. Source dates, methods and verification details are available within the interactive charts.